Research ExplorerPublicationsMetastatic spinal cord compression: a validated survival sco...

Metastatic spinal cord compression: a validated survival score for elderly patients

Standard

Metastatic spinal cord compression: a validated survival score for elderly patients. / Rades, Dirk; Evers, Jasmin N; Bajrovic, Amira; Veninga, Theo; Karstens, Johann H; Schild, Steven E.

In: STRAHLENTHER ONKOL, Vol. 190, No. 10, 10.2014, p. 919-24.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Evers, JN, Bajrovic, A, Veninga, T, Karstens, JH & Schild, SE 2014, 'Metastatic spinal cord compression: a validated survival score for elderly patients', STRAHLENTHER ONKOL, vol. 190, no. 10, pp. 919-24. https://doi.org/10.1007/s00066-014-0641-1

APA

Rades, D., Evers, J. N., Bajrovic, A., Veninga, T., Karstens, J. H., & Schild, S. E. (2014). Metastatic spinal cord compression: a validated survival score for elderly patients. STRAHLENTHER ONKOL, 190(10), 919-24. https://doi.org/10.1007/s00066-014-0641-1

Vancouver

Rades D, Evers JN, Bajrovic A, Veninga T, Karstens JH, Schild SE. Metastatic spinal cord compression: a validated survival score for elderly patients. STRAHLENTHER ONKOL. 2014 Oct;190(10):919-24. https://doi.org/10.1007/s00066-014-0641-1

Bibtex

@article{e90cdc7c403c47d5be5faffe0353b43e,
title = "Metastatic spinal cord compression: a validated survival score for elderly patients",
abstract = "BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC).PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor.RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001).CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.",
keywords = "Age Distribution, Aged, Aged, 80 and over, Carcinoma, Causality, Female, Geriatric Assessment, Germany, Humans, Incidence, Male, Prognosis, Proportional Hazards Models, Radiotherapy, Conformal, Reproducibility of Results, Risk Assessment, Sensitivity and Specificity, Spinal Cord Compression, Spinal Cord Neoplasms, Survival Analysis, Treatment Outcome",
author = "Dirk Rades and Evers, {Jasmin N} and Amira Bajrovic and Theo Veninga and Karstens, {Johann H} and Schild, {Steven E}",
year = "2014",
month = oct,
doi = "10.1007/s00066-014-0641-1",
language = "English",
volume = "190",
pages = "919--24",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "10",

}

RIS

TY - JOUR

T1 - Metastatic spinal cord compression: a validated survival score for elderly patients

AU - Rades, Dirk

AU - Evers, Jasmin N

AU - Bajrovic, Amira

AU - Veninga, Theo

AU - Karstens, Johann H

AU - Schild, Steven E

PY - 2014/10

Y1 - 2014/10

N2 - BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC).PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor.RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001).CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.

AB - BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC).PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor.RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001).CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.

KW - Age Distribution

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma

KW - Causality

KW - Female

KW - Geriatric Assessment

KW - Germany

KW - Humans

KW - Incidence

KW - Male

KW - Prognosis

KW - Proportional Hazards Models

KW - Radiotherapy, Conformal

KW - Reproducibility of Results

KW - Risk Assessment

KW - Sensitivity and Specificity

KW - Spinal Cord Compression

KW - Spinal Cord Neoplasms

KW - Survival Analysis

KW - Treatment Outcome

U2 - 10.1007/s00066-014-0641-1

DO - 10.1007/s00066-014-0641-1

M3 - SCORING: Journal article

C2 - 24658606

VL - 190

SP - 919

EP - 924

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 10

ER -